Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Rating of “Buy” by Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a consensus recommendation of “Buy” from the six brokerages that are covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $115.00.

A number of research firms have recently commented on LNTH. Truist Financial reissued a “buy” rating and set a $110.00 price target on shares of Lantheus in a report on Wednesday, October 4th. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a report on Monday, November 6th. Mizuho reissued a “buy” rating and set a $125.00 price target on shares of Lantheus in a report on Wednesday, October 4th. TheStreet raised Lantheus from a “c” rating to a “b-” rating in a report on Wednesday, August 9th. Finally, B. Riley reaffirmed a “buy” rating and issued a $113.00 target price on shares of Lantheus in a report on Tuesday, October 3rd.

Lantheus Price Performance

Lantheus stock opened at $69.12 on Thursday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.05 and a current ratio of 5.37. Lantheus has a 52 week low of $47.46 and a 52 week high of $100.85. The stock has a market capitalization of $4.73 billion, a P/E ratio of 48.40 and a beta of 0.66. The stock has a fifty day moving average of $66.53 and a 200-day moving average of $77.17.

Insider Activity

In other news, insider Daniel Niedzwiecki sold 2,846 shares of the stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $66.43, for a total value of $189,059.78. Following the completion of the sale, the insider now owns 66,295 shares of the company’s stock, valued at $4,403,976.85. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, President Paul Blanchfield sold 1,500 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $67.96, for a total transaction of $101,940.00. Following the sale, the president now owns 88,651 shares in the company, valued at approximately $6,024,721.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Daniel Niedzwiecki sold 2,846 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $66.43, for a total value of $189,059.78. Following the sale, the insider now owns 66,295 shares in the company, valued at approximately $4,403,976.85. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,467 shares of company stock valued at $1,063,299. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Institutional investors and hedge funds have recently made changes to their positions in the business. Altshuler Shaham Ltd bought a new stake in shares of Lantheus during the 2nd quarter valued at about $27,000. Covestor Ltd boosted its holdings in Lantheus by 102.5% in the second quarter. Covestor Ltd now owns 324 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 164 shares in the last quarter. SJS Investment Consulting Inc. boosted its holdings in Lantheus by 6,460.0% in the second quarter. SJS Investment Consulting Inc. now owns 328 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 323 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in Lantheus by 60.2% in the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 160 shares in the last quarter. Finally, AlphaMark Advisors LLC boosted its holdings in Lantheus by 456.3% in the first quarter. AlphaMark Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 365 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.